Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
DT2216 is a Selective PROTAC Degrader of BCL-XL - Network of Cancer ...
PROTAC protein degrader DT2216
DT2216 | BCL-XL PROTAC Degrader |CAS 2365172-42-3| DC Chemicals
DT2216 binds to both BCL-XL and BCL-2 but cannot degrade BCL-2 a, The ...
Characteristics of the nanoengineered Bcl-xL targeted PROTAC DT2216 ...
(PDF) DT2216 - A Bcl-xL-specific degrader is highly active against Bcl ...
DT2216 selectively kills Bcl-xL-dependent TCL cell lines by degrading ...
DT2216 combined with ABT199 synergistically reduced blood engraftment ...
Frontiers | BCLXL PROTAC degrader DT2216 targets secondary plasma cell ...
DT2216 is a Selective PROTAC Degrader of BCL-XL | MedChemExpress
DT2216 degrades BCL-XL in a VHL- and proteasome-dependent manner a ...
The BCL-XL degradation by DT2216 is rapid and long lasting a ...
(PDF) BCLXL PROTAC degrader DT2216 targets secondary plasma cell ...
DT2216 is a BCL-XL-specific PROTAC and induces BCL-XL degradation ...
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical ...
DT2216 selectively degrades BCLXL in myeloma cells. (A) Immunoblot of ...
(PDF) BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in ...
DT2216 | BCL-XL PROTAC Degrader | CAS 2365172-42-3 | Selleck Chemicals
DT2216 | PROTAC-degrader of BCL-XL | CAS# 2365172-42-3 | anti-leukemia ...
DT2216 | PROTAC BCL-XL Degrader | MedChemExpress
BCL-xL Degrader DT2216 Is Effective in JAK2-Mutated AML Post-MPN Models ...
Resistance to the BCL-XL Degrader DT2216 in T-cell Acute Lymphoblastic ...
Abstract B004: Phase 1b trial of BCL-XL degrader DT2216 and weekly ...
The PROTAC DT2216 Targets Cancer by Promoting BCL-XL Degradation ...
DT2216 induces apoptosis in myeloma cells through BAK and BAX ...
The combination of DT2216 and AZD8055 has stronger antitumor responses ...
VHL‐based PROTAC‐BCL‐XL DT2216 is also active in killing... | Download ...
A combination of sotorasib and DT2216 has synergistic antitumor ...
DT2216 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
DT2216, a BCL-XL PROTAC, selectively induces BCL-XL degradation and ...
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL ...
First in human phase 1 study of DT2216, a selective BCL-xL degrader, in ...
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL ...
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor ...
(PDF) Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the ...
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of ...
Abstract CT063: First in human phase 1 study of DT2216, a selective BCL ...
Flow cytometric analysis of apoptosis in DT2216- and DT@NPs-treated ...
JCI Insight - Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
Development of a BCL-xL and BCL-2 dual degrader with improved anti ...
BCL-XL PROTAC leads to efficient degradation of BCL-X L in the tumor ...
DT2216+AZD8055 combination synergistically kills BCL-X L /MCL-1 ...
The enhanced effects of DT@NPs on the Bcl-xL targeted degradation in ...
靶向BCL-XL的蛋白降解疗法：选择性抑制肿瘤生长与血小板毒性规避策略-CSDN博客
Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 ...
化合物DT2216,DT2216 ,CAS : [2365172-42-3] - 生命科学产品与技术服务-生工生物工程(上海)股份有限公司
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly ...
BCL-XL PROTAC降解物DT2216在KRASG12C突变的癌症临床前模型中与sotorasib协同作用 - 知乎
首款BCL-XL降解剂DT2216 I期数据揭晓：有效且更安全，破解实体瘤耐药难题 - MedFind
PROTAC Bcl-xL degrader-2 | PROTAC Bcl-xL Degrader | MedChemExpress
纳米脂质体 Bcl-xL 蛋白水解靶向嵌合体可增强对宫颈癌和乳腺癌的抗癌作用而无靶向毒性,Advanced Composites and ...
A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and ...
Targeting BCL-XL in fibrolamellar hepatocellular carcinoma - PMC
